Biohaven Pharmaceutical Holding Company Ltd. BHVN 深 滬
等待開盤 12-20 09:30:00 美东时间
10.85
-0.280
-2.52%
華盛通- 最 高11.35
- 今 開11.20
- 成交量 508.78万股
- 最 低 10.825
- 昨 收 11.13
- 總市值 11.07亿
- 52周最高 44.2803
- 市盈率 靜 --
- 換手率 4.99%
- 52周最低 7.48
- 委 比 -88.68%
- 總股本 1.02亿
- 歷史最高 152.56
- 量 比 1.91
- 振 幅 4.72%
- 歷史最低 7.10
- 每 手 1
- 風險率 9.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
UBS Downgrades Biohaven to Neutral, Lowers Price Target to $11
UBS analyst Ashwani Verma downgrades Biohaven (NYSE:BHVN) from Buy to Neutral and lowers the price target from $26 to $11.
11-26 22:42
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Citigroup Maintains Buy on Biohaven, Lowers Price Target to $14
Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $28 to $14.
11-14 03:43
Biohaven Prices ~$175M Offering Of 23.3M Common Shares At $7.50/Share
Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases,
11-12 20:16
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Shares of LightPath Technologies Inc (NASDAQ:LPTH) rose sharply in pre-market t...
11-12 17:42
Biohaven shares are trading lower after the company announced a $150 million offering.
Biohaven shares are trading lower after the company announced a $150 million of...
11-12 05:12
Biohaven Announces $150M Common Stock Offering
Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases,
11-12 05:06
